Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific.
FAIL · Does not pass the screen
35.40 USD
Price as of 5 Nov 2026Daily close, not a live quote
Screened 2026-11-05 · the tape above runs as of 18:01 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
Price35.40 USD at the 5 Nov 2026 close
Our value readUndervalued vs our fair value, as of 5 Nov 2026
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.13, read 2026-11-03
Ethical does not pass the values gate
Price35.40 USD
Fair value55.00
Ethical score70.0/100
Value readUndervaluedas of 5 Nov 2026
Our investment reviews on this name
2026-10-11Read Accumulation34.68+2.1% to today ✓Markdown gives way to Accumulation
2026-10-02Read Markdown34.68+2.1% to today Accumulation gives way to Markdown
2026-08-08Read Accumulation33.31+6.3% to today ✓Distribution gives way to Accumulation after a 6% rise in 5 weeks
2026-07-02Read Distribution31.53+12.3% to today First review on file: Distribution
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Phibro Animal Health Corporation holds its Accumulation at $35.40. The statistical read favours the sellers, held for 82 days.
As held on the ledger · 2026-11-05
Phase
Accumulation
Quantitative state
The statistical read favours the sellers, held for 82 days
Price at the screen
$35.40
Valuation
14.27 trailing · 9.01 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.47
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
55.96%
Below 33%
Interest-bearing debt is 56.0% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.66%
Below 33%
Cash held in interest-bearing accounts and securities is 0.7% of assets, under the one-third limit.
Pass
Receivables
21.75%
Below 49%
Money owed to the company is 21.8% of assets, under the 49% limit.
Pass
Revenue purity
0.20%
Below 5%
Only 0.2% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Phibro Animal Health's business is in a permissible area, but its interest-bearing debt is about 56% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when PAHC's ethical verdict changes
Today PAHC does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 5 Nov 2026: it trades at roughly a 28% discount to our $55.00 fair value, 4.80% revenue growth.
Fair value range in USD, drawn from the 2026-11-05 screen. The gold marker is the market price at the same screen. A 35.6% discount to the base estimate.
Where our models see it going: fair-value estimate $55.00, with a range of $55.00 to $78.86, dated to the 2026-11-05 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Animal health firm priced below its worth
Every time a Midwest feedlot treats its cattle or an Asian poultry farm battles disease, Phibro supplies the medicines and mineral mixes that keep operations running. Shares sit at 10 times forward earnings with 10 percent revenue growth, a 6 percent profit margin and 30 percent return on equity, all while clearing the ethical screen and sitting well below our 55 dollar fair value.
Yet the opportunity rating is none. The unknown competitive position and thin margins leave too many open questions about durability, even though analyst targets sit at 44 dollars and the valuation looks attractive on paper.
Currency swings, farming cycles and limited visibility on long term pricing power keep the risk level elevated. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; as a drug manufacturers - specialty & generic name, trial and regulatory outcomes can move it sharply either way; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
PAHC trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-04Accumulation$37.65-3.2%Entry 17
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 3.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 31%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (5 analysts) rates it hold, with a mean price target of $46. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-03Accumulation$38.88+0.0%Entry 16
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 31%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (5 analysts) rates it hold, with a mean price target of $46. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-02Accumulation$38.88+0.0%Entry 15
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 31%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (5 analysts) rates it hold, with a mean price target of $46. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-01Accumulation$38.88+0.2%Entry 14
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 0.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 31%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (5 analysts) rates it hold, with a mean price target of $46. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-31Accumulation$38.80+0.0%Entry 13
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 31%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (5 analysts) rates it hold, with a mean price target of $46. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-30Accumulation$38.80+0.0%Entry 12
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 31%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (5 analysts) rates it hold, with a mean price target of $46. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-29Accumulation$38.80+2.3%Entry 11
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 2.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 31%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (5 analysts) rates it hold, with a mean price target of $46. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-28Accumulation$37.93+0.0%Entry 10
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 31%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (5 analysts) rates it hold, with a mean price target of $46. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25Accumulation$37.93+0.0%Entry 9
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 31%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (5 analysts) rates it hold, with a mean price target of $46.
2026-10-18Accumulation$37.93+9.4%Entry 8
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 9.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 27% above its long-term trend line with momentum reading oversold. Over the past year the shares are up 31%. Our forward projection puts the odds of a 10% gain over the next month near 34%. The street (5 analysts) rates it hold, with a mean price target of $46.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
